Cargando…
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Standard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory effects, there is a growing interest to combine chemotherapy a...
Autores principales: | Ding, Zhi-Chun, Zhou, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286900/ https://www.ncbi.nlm.nih.gov/pubmed/22400040 http://dx.doi.org/10.1155/2012/890178 |
Ejemplares similares
-
IL7 signaling confers polyfunctionality to antitumor CD4+ T cells
por: Zhou, Gang, et al.
Publicado: (2014) -
Hypoxia and antitumor CD8(+) T cells: An incompatible alliance?
por: Vuillefroy de Silly, Romain, et al.
Publicado: (2016) -
CD4(+) cytotoxic T cells: an emerging effector arm of anti-tumor immunity
por: Jeong, Seongmin, et al.
Publicado: (2023) -
Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox
por: Oh, David Y., et al.
Publicado: (2021) -
CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4(+) T cells
por: Hao, Yuwei, et al.
Publicado: (2023)